- Conditions
- Obesity
- Interventions
- Comprehensive weight loss, Enhanced lifestyle changes, Tirzepatide, Naltrexone-Bupropion, Phentermine-Topiramate, Semaglutide (Wegovy®)
- Other · Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 58
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Obesity, Smoking Cessation, Bariatric Surgery Patients
- Interventions
- Naltrexone Hydrochloride, Bupropion HCl Extended Release, Cognitive-Behavioral Therapy
- Drug · Behavioral
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Obesity, Overweight
- Interventions
- Naltrexone SR 32 mg/bupropion SR 360 mg/day, Placebo, Ancillary therapy
- Drug · Behavioral
- Lead sponsor
- Orexigen Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,496 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Hot Springs, Arkansas • Carmichael, California + 31 more
- Conditions
- Weight Regain Post Bariatric Surgery
- Interventions
- Naltrexone HCl/Bupropion HCl Placebo, Naltrexone HCl/Bupropion HCl
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Boston, Massachusetts
- Conditions
- Schizophrenia, Diabetes Mellitus, Type 2, Obesity
- Interventions
- Naltrexone, Bupropion, Placebo
- Drug · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Depression
- Interventions
- naltrexone SR 32 mg/ bupropion SR 360 mg daily
- Drug
- Lead sponsor
- Orexigen Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Mason, Ohio
- Conditions
- Cocaine Use Disorders
- Interventions
- Bupropion
- Drug
- Lead sponsor
- Craig Rush
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Loss-of-Control Eating, Obesity/Overweight
- Interventions
- Naltrexone and Bupropion (NB) medication, Placebo
- Drug · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Binge Eating Disorder
- Interventions
- Naltrexone and bupropion combination, Pill Placebo
- Drug · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Obesity
- Interventions
- Semaglutide, Orlistat, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- Endometrial Cancer Survivors, Weight Management, Early Stage Endometrial Cancer
- Interventions
- Weight loss with pharmacotherapy, Weight loss without pharmacotherapy
- Behavioral
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Obesity, Overweight
- Interventions
- Behavioral Weight Loss (BWL), Early Responder: BWL continued, Early Non-responder: BWL continued with medication added
- Behavioral · Combination Product
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Type 2 Diabetes, Obesity
- Interventions
- Weight Management Program (WMP), Traditional care, Phentermine / Topiramate Extended Release Oral Capsule, naltrexone/bupropion extended-release, liraglutide 3.0 mg, Orlistat
- Other · Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Pregnancy, Obesity, Overweight
- Interventions
- No Intervention
- Other
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 15 Years to 50 Years · Female only
- Enrollment
- 2,701 participants
- Timeline
- 2020 – 2027
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Princeton, New Jersey
- Conditions
- Obesity
- Interventions
- Naltrexone and Bupropion Combination, Behavioral Weight Loss, Placebo
- Drug · Behavioral · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Obesity, Overweight
- Interventions
- NB, CLI, Usual Care
- Drug · Behavioral
- Lead sponsor
- Orexigen Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 15
- States / cities
- Denver, Colorado • St Louis, Missouri • Cary, North Carolina + 12 more
- Conditions
- Binge-Eating Disorder, Obesity
- Interventions
- NB medication (Naltrexone Bupropion combination), Placebo
- Drug · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Obesity
- Interventions
- Intervention Control, Counselling, Contrave, Contrave and Counseling
- Behavioral · Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 65 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 2
- States / cities
- Scottsbluff, Nebraska
- Conditions
- Obesity
- Interventions
- Weight Management Program (WMP), Medication for chronic weight management (Rx)
- Other · Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Methamphetamine-dependence, Methamphetamine Abuse
- Interventions
- extended-release naltrexone (XR-NTX), extended release bupropion (BUP-XL) tablets (BUP-XL), iPLB, oPLB
- Drug
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 11
- States / cities
- Little Rock, Arkansas • Los Angeles, California • San Diego, California + 8 more
- Conditions
- Healthy
- Interventions
- Reference naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets), Test naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)
- Drug
- Lead sponsor
- Orexigen Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Binge-Eating Disorder, Obesity
- Interventions
- Cognitive-Behavioral Therapy (CBT), NB Medication (on-going from acute treatment)
- Behavioral · Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Binge-Eating Disorder, Obesity
- Interventions
- Naltrexone and Bupropion, Placebo
- Drug · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Stimulant Use, Relapse, Cognitive Function, ADHD
- Interventions
- Contrave 8Mg-90Mg Extended-Release Tablet, Bupropion
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California